Brief: Cero Therapeutics Receives FDA Fast Track Designation For Cer-1236 In Acute Myeloid Leukemia (Aml)
05/09/2025 15:44
CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR CER-1236 IN ACUTE MYELOID LEUKEMIA (AML) Source text: ID:nGNE3HQH8l Further company coverage: CERO.O
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List